Neurotoxic and neuroprotective actions of catecholamines in cortical neurons.
We examined the possibility that catecholamines (CA) could act as endogenous modulators of neuronal death. Exposure to high doses (>100 microM) of dopamine (DA) caused widespread neuronal death within 24 h in mouse cortical cell cultures and was accompanied by cell body shrinkage, aggregation and condensation of nuclear chromatin, and prominent internucleosomal DNA fragmentation. Epinephrine, but not norepinephrine (NE), was slightly toxic to neurons at doses higher than 1 mM. DA-induced death was attenuated by the addition of three different anti-apoptosis agents, 1 microgram/ml cycloheximide, 25 mM K(+), or 100 ng/ml brain-derived neurotrophic factor (BDNF). While treatment with 100 microM N-acetyl-l-cysteine attenuated DA neurotoxicity, neither the glutamate antagonists (10 microM MK-801 plus 50 microM CNQX) nor several antioxidants [trolox, 100 microM; Mn (III) tetrakis (4-benzoic acid) porphyrin chloride, 100 microM; Mn (III) tetrakis (1-methyl-4-pyridyl) prophyrin pentachloride, 100 microM; N-tert-butyl-alpha-phenylnitrone, 3 mM] prevented the CA-induced apoptosis. Interestingly, all CA at 1-30 microM attenuated free radical-mediated neuronal necrosis following exposure to 30 microM Fe(2+) or 200 microM H(2)O(2), which was insensitive to DA or NE antagonists. Like trolox, CA reduced levels of the stable free radical 1,1-diphenyl-2-picrylhydrazyl under cell-free conditions, raising the possibility that CA as an antioxidant protects neurons. We also found that the neuroprotective effect of CA prolonged the protective effects of BDNF against serum deprivation. The present findings suggest that CA induces apoptosis at high doses but prevents free radical-mediated neurotoxicity as an anti-oxidant without being coupled to the receptors.
Noh
J S
JS
Department of Psychiatry and Behavioral Sciences, Ajou University, School of Medicine, Suwon, Kyungkido, 442-749, Korea.
Kim
E Y
EY
Kang
J S
JS
Kim
H R
HR
Oh
Y J
YJ
Gwag
B J
BJ
D000111:Acetylcysteine / Q000378:metabolism; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D019208:Brain-Derived Neurotrophic Factor / Q000494:pharmacology; D002316:Cardiotonic Agents / Q000633:toxicity; D002395:Catecholamines / Q000633:toxicity*; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D002540:Cerebral Cortex / Q000166:cytology; D003513:Cycloheximide / Q000494:pharmacology; D004249:DNA Damage; D004298:Dopamine / Q000633:toxicity; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004837:Epinephrine / Q000633:toxicity; D005333:Fetus / Q000166:cytology; D005609:Free Radicals / Q000378:metabolism; D015227:Lipid Peroxidation; D051379:Mice; D009474:Neurons / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D009638:Norepinephrine / Q000633:toxicity; D011188:Potassium / Q000494:pharmacology; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D013566:Sympathomimetics / Q000633:toxicity
D019208:Brain-Derived Neurotrophic Factor; D002316:Cardiotonic Agents; D002395:Catecholamines; D005609:Free Radicals; D011500:Protein Synthesis Inhibitors; D013566:Sympathomimetics; D003513:Cycloheximide; D011188:Potassium; D004298:Dopamine; D000111:Acetylcysteine; D009638:Norepinephrine; D004837:Epinephrine